Key Takeaways from CDE’s Draft Guideline on Pharmaceutical Research for Rare Diseases

On August 14, 2025, China’s Center for Drug Evaluation (CDE) released the draft guideline "Guiding Principles for Pharmaceutical Research of Chemical Drugs for Rare Diseases" for public consultation. The draft introduces risk-based flexibilities to address the unique challenges of developing therapies for small patient populations while maintaining rigorous quality standards, reflecting CDE’s ongoing commitment to advancing regulatory science for rare diseases.

Highlights of the Draft Guideline

The draft proposes provisions ranging from manufacturing to regulatory engagement to better support rare disease drug development.

Key provisions include:

1. Production Batch Size: Flexibility to Align with Market Realities

Traditional large-scale batch requirements often create inefficiencies for rare disease products. The draft guideline allows applicants to define batch sizes based on epidemiology, projected demand, and commercial feasibility, reducing unnecessary cost and waste.

2. Process Validation: Representative Data and Risk-Based Justification

• Expanded Data Sources: Validation may leverage clinical trial or development batches, provided they are representative of commercial-scale production.
• Risk Assessment: Applicants must demonstrate representativeness through robust risk assessments. They should also provide evidence that critical process parameters and quality attributes can scale appropriately.

3. Stability Studies: Optimized Strategies to Accelerate Development

• Use of Prior Knowledge and Bridging Data: Sponsors are encouraged to apply existing stability data or comparability studies. This approach helps minimise redundant testing.
• Rolling Submission: Sponsors may submit stability data incrementally during review or post-approval, subject to agreement with CDE, supporting accelerated timelines.

4. Registration Testing: Reduced Burden

• Lower Batch and Sample Requirements: Applicants now submit only one batch for registration testing instead of three. Sample volume requirements are also decreased..
• Multiple API Sources: Where multiple API manufacturers are involved, one batch per source is recommended for testing.

5. Regulatory Engagement: Early and Continuous Dialogue

• Strategic Interactions: Sponsors should engage CDE at critical milestones, such as pre-pivotal trials and pre-NDA submissions. This ensures alignment on issues including starting material designation, impurity control, batch sizing, and stability protocols.
• Facilitating Expedited Pathways: For products under priority review or breakthrough designation, rolling submissions are encouraged. These are based on prior agreements and help shorten review timelines.

Context and Significance

This draft complements earlier CDE guidelines, including:

• Clinical Development of Drugs for Rare Diseases (January 2022)
• Clinical Pharmacology Research of Drugs for Rare Diseases and Model-Informed Drug Development (July 2025)

Together, these documents establish a comprehensive regulatory framework for rare disease drug development in China—spanning pharmaceutical research, clinical pharmacology, and clinical studies—and underscore the agency’s commitment to a science-based, patient-focused approach.